Almirall, S.a.

Laboratorios Almirall, S.a.

Almirall Prodesfarma S.a.

Cristina Esteve Trias

Bernat Vidal Juan

Jacob Gonzalez Rodriguez

Paul Robert Eastwood

Jordi Gracia Ferrer

Joan Taltavull Moll

José Manuel Prieto Soto

New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).

2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors

New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy. 

3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives

This invention is directed to selective antagonists of Aand/or Aadenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy. 

Substituted-4-(pyrrolo pyrimidin-6-yl)benzenesulphonamide derivatives

This invention relates to new therapeutically useful 8-(disubstituted)phenyl-6,9-dihydro-5H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one and 8-phenyl-6,9-dihydro-5H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one derivatives of formula (I): wherein: &#x2014;X&#x2014;C&#x2014;Y&#x2014; represents (a) or (b) to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medical uses as potent and selective inhibitors of phosphodiesterase 5 (PDE 5).

Growing community of inventors

Barcelona, Spain

Cristina Esteve Trias